(Q53210224)

12 May 2018

title

Association of genetic variants in six candidate genes with valproic acid therapy optimization. (English)

1 reference

12 May 2018

author

Horng-huei Liou

7

1 reference

12 May 2018

author name string

Chin-Chuan Hung

1

1 reference

12 May 2018

Jia-Ling Ho

2

1 reference

12 May 2018

Wei-Lun Chang

3

1 reference

12 May 2018

John Jen Tai

4

1 reference

12 May 2018

Tsung-Jen Hsieh

5

1 reference

12 May 2018

Yow-Wen Hsieh

6

1 reference

12 May 2018

publication date

1 August 2011

1 reference

12 May 2018

published in

Pharmacogenomics

1 reference

12 May 2018

volume

12

1 reference

12 May 2018

issue

8

1 reference

12 May 2018

page(s)

1107-1117

1 reference

12 May 2018

Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action

cites work

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview

21 January 2018

1 reference

Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy

21 January 2018

1 reference

Mechanisms of action of valproate: a commentatory

21 January 2018

1 reference

Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects

21 January 2018

1 reference

The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases

21 January 2018

1 reference

Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10

21 January 2018

1 reference

4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7

21 January 2018

1 reference

Sequence Variability and Candidate Gene Analysis in Two Cancer Patients with Complex Clinical Outcomes During Morphine Therapy

21 January 2018

1 reference

Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance

21 January 2018

1 reference

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.

21 January 2018

1 reference

UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S).

21 January 2018

1 reference

Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6.

21 January 2018

1 reference

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

21 January 2018

1 reference

Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A.

21 January 2018

1 reference

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

21 January 2018

1 reference

Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

21 January 2018

1 reference

Association between NR2B subunit gene (GRIN2B) promoter polymorphisms and sporadic Alzheimer's disease in the North Chinese population

21 January 2018

1 reference

Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing.

21 January 2018

1 reference

Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells

21 January 2018

1 reference

Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia

21 January 2018

1 reference

UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients

21 January 2018

1 reference

Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays.

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.

21 January 2018

1 reference

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

21 January 2018

1 reference

Predicting response to lithium in mood disorders: role of genetic polymorphisms

21 January 2018

1 reference

Clinical response to morphine in cancer patients and genetic variation in candidate genes

21 January 2018

1 reference

Factors influencing cyclosporine blood concentration-dose ratio

21 January 2018

1 reference

Statistical design and analysis of pharmacogenetic trials

21 January 2018

1 reference

Fatty Acid Transfer from Liver and Intestinal Fatty Acid-binding Proteins to Membranes Occurs by Different Mechanisms

21 January 2018

1 reference

A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.11.64

1 reference

12 May 2018

1 reference

12 May 2018